Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients

Table 2 Association of anti-PD1 with clinical features of new-onset SLE patients

Clinical manifestations	p value	Odds ratio	95% CI
Malar rash	0.001	15.773	3.065–81.186
Discoid rash	0.077	12.688	0.762–211.274
Arthritis	<0.001	22.937	4.619–113.9
Oral ulcer	0.279	3.830	0.336–43.256
Photosensitivity	0.477	4.042	0.086–189.971
Vasculitis	0.216	4.851	0.398–59.109
Raynaud’s phenomenon	0.657	2.266	0.061–84.212
Serositis	0.007	16.008	2.119–120.967
Hematological involvement	<0.001	35.187	6.459–191.679
Renal involvement	0.024	8.306	1.323–52.132
Neurological involvement	0.027	37.282	1.497–928.697